From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
Variable
Reduced
Active
Tamoxifen
Median (Low/upper quartile)
No tamoxifen
Ki-67 change
2.5 (-2/7)
0 (-5/2)
-2.5 (-10/0)
0 (-1/4)